Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

Identification of a Poor-PrognosisBRAF-Mutant–Like Population of Patients With Colon Cancer

(2012) Vlad Popovici et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer

(2011) Richard G. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803

(2011) Monica M. Bertagnolli et al.   JOURNAL OF CLINICAL ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

(2009) M Koopman et al.   BRITISH JOURNAL OF CANCER

Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial

(2009) F. T. Bosman et al.   CLINICAL CANCER RESEARCH

The role of SMAD4 in early-onset colorectal cancer

(2009) S. G. Royce et al.   Colorectal Disease

Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All

(2009) Sumithra J. Mandrekar et al.   Journal of Biopharmaceutical Statistics

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers

(2009) Shuji Ogino et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803

(2009) Monica M. Bertagnolli et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data

(2009) Leonard L. Gunderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Basis of Colorectal Cancer

(2009) Sanford D. Markowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis

(2008) Gerta Rücker et al.   BMC Medical Research Methodology

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and predictive factors in colorectal cancer

(2008) I Zlobec et al.   POSTGRADUATE MEDICAL JOURNAL